Hepatitis B core-based virus-like particles : A platform for vaccine development in plants
© 2021 The Authors. Published by Elsevier B.V..
Virus-like particles (VLPs) are a class of structures formed by the self-assembly of viral capsid protein subunits and contain no infective viral genetic material. The Hepatitis B core (HBc) antigen is capable of assembling into VLPs that can elicit strong immune responses and has been licensed as a commercial vaccine against Hepatitis B. The HBc VLPs have also been employed as a platform for the presentation of foreign epitopes to the immune system and have been used to develop vaccines against, for example, influenza A and Foot-and-mouth disease. Plant expression systems are rapid, scalable and safe, and are capable of providing correct post-translational modifications and reducing upstream production costs. The production of HBc-based virus-like particles in plants would thus greatly increase the efficiency of vaccine production. This review investigates the application of plant-based HBc VLP as a platform for vaccine production.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Biotechnology reports (Amsterdam, Netherlands) - 29(2021) vom: 15. März, Seite e00605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moradi Vahdat, Maryam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hepatitis B core |
|---|
| Anmerkungen: |
Date Revised 20.03.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.btre.2021.e00605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322892155 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322892155 | ||
| 003 | DE-627 | ||
| 005 | 20231225183014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.btre.2021.e00605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322892155 | ||
| 035 | |a (NLM)33732633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moradi Vahdat, Maryam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B core-based virus-like particles |b A platform for vaccine development in plants |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Published by Elsevier B.V. | ||
| 520 | |a Virus-like particles (VLPs) are a class of structures formed by the self-assembly of viral capsid protein subunits and contain no infective viral genetic material. The Hepatitis B core (HBc) antigen is capable of assembling into VLPs that can elicit strong immune responses and has been licensed as a commercial vaccine against Hepatitis B. The HBc VLPs have also been employed as a platform for the presentation of foreign epitopes to the immune system and have been used to develop vaccines against, for example, influenza A and Foot-and-mouth disease. Plant expression systems are rapid, scalable and safe, and are capable of providing correct post-translational modifications and reducing upstream production costs. The production of HBc-based virus-like particles in plants would thus greatly increase the efficiency of vaccine production. This review investigates the application of plant-based HBc VLP as a platform for vaccine production | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Hepatitis B core | |
| 650 | 4 | |a Plant expression system | |
| 650 | 4 | |a VLP-based vaccine | |
| 650 | 4 | |a Virus-like particle | |
| 700 | 1 | |a Hemmati, Farshad |e verfasserin |4 aut | |
| 700 | 1 | |a Ghorbani, Abozar |e verfasserin |4 aut | |
| 700 | 1 | |a Rutkowska, Daria |e verfasserin |4 aut | |
| 700 | 1 | |a Afsharifar, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Eskandari, Mohammad Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nahid |e verfasserin |4 aut | |
| 700 | 1 | |a Niazi, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnology reports (Amsterdam, Netherlands) |d 2014 |g 29(2021) vom: 15. März, Seite e00605 |w (DE-627)NLM241422434 |x 2215-017X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g day:15 |g month:03 |g pages:e00605 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.btre.2021.e00605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |b 15 |c 03 |h e00605 | ||